In a multi-CAR-T cell therapy regimen study designed to prevent antigen-negative relapses, primary, booster, and/or consolidation CAR-T infusions targeting CD19, CD22, CD30, GD2, and/or PSMA (all with co-stimulatory signals for CD28 and CD27) were developed based on the evaluation of pre-treatment and during treatment antigen expression of tumor biopsies of lymphoma patients [86]. This evidence concerns the gene CD28 and lymphoma.